Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Hormonal changes at puberty may trigger disease activity, but DMTs reduced the risk, indicating more aggressive treatment may be warranted.

Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

in Ireland for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease.1 BRIUMVI® is a novel monoclonal antibody that targets a unique epitope on CD20-expressing ...

The aim of this study is to explore and describe patient-reported experiences of DMD in daily life in patients with MS. For the purpose of decreasing progression of multiple sclerosis (MS ... oral ...

Multiple sclerosis (MS) is one of the most widespread disabling neurological conditions of young adults around the world. It affects almost 1 million people in the United States, and about 2.9 ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

Researchers don’t yet fully understand what causes multiple sclerosis (MS) but believe it may develop from a combination of genetic and environmental factors. Identifying these factors can help ...

infusions, and oral medications targeting different sites in the inflammatory pathway.” RELATED: CNN Anchor John King, 60, Reports in the Field While Managing Multiple Sclerosis — Suffering Quietly ...